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ABSTRACT
Objective: The objective of this study was to determine whether prophylactic treatment with oral
broad-spectrum antimicrobial therapy improves pregnancy outcomes in twin gestations.
Methods: Patients with twin gestations between 24 and 32 weeks were randomized to receive
amoxicillin/clavulanic acid or placebo. Those patients randomized before 24 weeks received a
1-week course at 24 and at 28 weeks gestation. Those patients entered later than 24 weeks received
a 1-week course either at 28 weeks or at enrollment (up to 32 weeks). Other than antibiotic use, the
management of the groups was identical and unchanged from the routine care of twin gestations.
Results: Of 149 twin pregnancies enrolled, 76 were randomized to the drug group and 73 to the
placebo group. There was no significant difference in mean gestational age at delivery (35.9 vs. 35.7
weeks), birth weight (2,358 vs. 2,344 g), mean neonatal nursery stay (9.9 vs. 11.7 days), or respira-
tory distress syndrome (6/76 vs. 4/73) in the drug vs. placebo group, respectively.
Conclusions: The addition of prophylactic oral broad-spectrum antimicrobial therapy to the stan-
dard antepartum management of twin gestations had no demonstrable effect on the gestational age
at delivery, birth weight, or neonatal complications. There did not appear to be any beneficial effect
of the prophylactic use of amoxicillin/clavulanic acid in this clinical setting. (C) 1995 Wiley-Liss, Inc.
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ultiple gestation is an important risk factor for
preterm labor and delivery with the rate of
preterm delivery 2-5 times greater than the rate of
singleton pregnancies. The etiology of preterm
birth is unknown, although recent reports have
implicated infection as a possible cause.
2-s Ran-
domized clinical trials using antibiotics in hospital-
ized women with singleton gestations and preterm
labor have suggested a significant prolongation in
gestation in the treated groups.
3-s Women ran-
domized to a course of erythromycin or placebo as
adjunctive therapy to tocolysis also showed strong sta-
tistical trends toward larger birth weights, reduced
nursery days, and reduced maternal readmissions for
preterm labor in the drug-treated women.
In addition, it has been hypothesized that me-
chanical forces in twin pregnancy may cause pre-
mature cervical dilation which may increase the
likelihood of ascending infections. Romero and co-
workers
6 found that 11.9% of amniotic-fluid cul-
tures from twin gestations with preterm labor were
positive. The purpose of this randomized, con-
trolled trial was to study the effect of prophylactic
antibiotic treatment in twin gestations.
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SUBJECTS AND METHODS
Study Population
The subjects for this study were selected from the
population ofwomen presenting for obstetrical care
at Parkland Memorial Hospital, Dallas, TX, be-
tween November 1, 1989, and December 1, 1992.
These women, all residents of Dallas County, were
determined to be economically disadvantaged when
they presented for prenatal care at one of the satel-
lite prenatal clinics.
The study was approved by the institutional re-
view board at the University of Texas Southwest-
ern Medical Center. All twin pregnancies diag-
nosed antenatally in the Parkland Memorial
Hospital clinic system were referred to the twin
clinic for further evaluation and prenatal care. A
patient was considered for enrollment if the esti-
mated gestational age was <33 weeks. The criteria
for exclusion were fetal structure abnormalities and
monoamnionicity or twin intrapair weight discor-
dancy >25% by ultrasound. In addition, a patient
was excluded if she had a medical complication
such as hypertension, diabetes, hyperthyroidism,
or cardiac disease or if she had an allergy to penicil-
lin. A patient was also excluded if she was unable to
give informed consent in either English or Span-
ish. Women who met the study criteria were asked
to participate, and written informed consents in
English or Spanish were obtained.
Experimental Design
The patients were divided into 2 subgroups based
upon gestational age at entry in the study. The
patients in the first subgroup were enrolled <24
weeks gestation. These patients were randomized to
receive either amoxicillin, 500 mg/clavulanic acid,
125 mg, or placebo (vitamin C, 500 mg) every 8 h
for 7 days in their 24th week of pregnancy and
again in their 28th week of pregnancy. Those pa-
tients who were enrolled >24 weeks but <33 weeks
gestation were randomized to receive a single week-
long course of amoxicillin/clavulanic acid or pla-
cebo regimen either at the 28th week or at the time
of enrollment (up to 32 weeks). This subgrouping
was necessary because our obstetrical clinics do not
employ "universal sonography," resulting in many
cases of twins not being diagnosed until the third
trimester. The drug was administered in a double-
blinded fashion. A patient’s compliance was as-
sessed by counting the number of pills left at the
following clinic visit. She was considered compli-
ant if she had taken more than half of her pills.
The standard protocol for following all twin
gestations in this clinic was not changed for the
management of the study patients. Specifically, the
prenatal laboratory work for a patient presenting to
a neighborhood obstetrical clinic in Dallas County
included a cervical Neisseria gonorrhoeae culture,
a urine culture, and syphilis serology. After the
diagnosis of twins was made, the patient was re-
ferred to a centralized clinic at Parkland Memorial
Hospital. The prenatal care at the centralized clinic
consisted of 1) weekly visits after 22 weeks gesta-
tion including digital cervical examinations per-
formed by an attending staff member or resident,
2) ultrasound examinations at 3-4-week intervals,
3) iron and folate supplementation, and 4) hospital-
ization for medical or obstetrical indications such as
preeclampsia, hydramnios, or >25% discordance
of estimated fetal weight on ultrasound. Addition-
ally, any woman presenting with preterm labor or a
cervical score (cervical dilation in cm subtracted
from the cervical length in cm) <0 on her clinic
cervical examination was admitted to labor and de-
livery at Parkland Memorial Hospital.
7 If not in
active labor on admission, she was hospitalized at
bed rest until her 32nd week of gestation. No toco-
lytics or steroids for fetal lung development were
used. The time ofdelivery was determined by med-
ical or obsterical indications. In the absence ofcom-
plications, she was delivered electively between 39
and 40 weeks gestation. The route of delivery was
decided by the responsible staff physician when the
woman presented to the labor and delivery area.
The data regarding pregnancy outcomes were ab-
stracted from the hospital charts of the mothers and
neonates.
Statistical Analysis
A power analysis was performed prospectively. As-
suming a preterm delivery rate of50% (<36 weeks)
and assuming that all preterm deliveries were caused
by infection, we determined that 45 patients would
be required in each group to demonstrate a halving
of the preterm delivery rate to 25% with 80%
power and an ot error at the 5% significance level.
Prospectively assuming a 25-50% noncompliance
factor, we planned to enroll 75 patients per group
to account for noncompliance. A comparison of the
compliance of the groups was made using Fisher’s
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TABLE I. Maternal demographics
Characteristics Total
Amoxicillin/clavulanic acid
24-week entry 28-week entry
Placebo
Total 24-week entry 28-week entry
No. of subjects (%) 76 (100) 41 (100)
Mean age (years) 25.4 25.5
Gravidity >1 (%) 57 (75) 31 (76)
Race
Black (%) 27 (36) 15 (37)
White (%) 19 (25) 13 (32)
Hispanic (%) 29 (38) 12 (29)
Oriental (%) (I) (2)
35 (100) 73 (100) 36 (100) 37 (100)
25.3 25.5 25.4 25.5
26 (74) 58 (80) 28 (78) 30 (81)
12 (34) 26 (36) 13 (36) 13 (35)
6 (17) 13 (17) 6 (17) 7 (19)
17 (49) 34 (47) 17 (47) 17 (46)
o (o) o (o) o (o) o (o)
exact test. The groups were compared for maternal
age with the Student’s t-test, for gravidity with the
exact linear-by-linear trend test, and for race or
ethnicity using the (2 4) Fisher’s exact test. The
birth weights were compared using a repeated-mea-
sures analysis of variance that included a within-
subjects effect for the twins. A nursery stay >6
days was evaluated using a repeated-measures strat-
egy for categorical data. The incidence of respira-
tory distress syndrome and neonatal sepsis was eval-
uated using chi-squared analysis.
RESULTS
During the 37-month study, 149 patients with twin
pregnancies were enrolled, with 76 receiving
amoxicillin/clavulanic acid and 73 receiving pla-
cebo. Seventy-seven were randomized <24 weeks
gestation and given 2 courses of drugs. Of these 77
patients, 41 received amoxicillin/clavulanic acid and
36 received placebo. In the 72 patients randomized
>24 weeks gestation (28-32 weeks), 35 patients
received amoxicillin/clavulanic acid and 37 received
placebo. Eight patients were lost to follow-up, 5 in
the drug group and 3 in the placebo group. No
maternal or neonatal data were available for 6 who
delivered elsewhere. The other 2 were delivered at
Parkland Memorial Hospital, but their neonatal
records could not be located. Both of these sets of
twins were admitted to the normal newborn nurs-
ery, presumably with no significant problems. The
treatment regimens were generally well tolerated.
Thirty patients reported adverse effects including
nausea and vomiting (9/30) and diarrhea (9/30).
There were no serious adverse effects, although 16
subjects stated they discontinued treatment before
completing the course due to side effects. Of these
16 subjects, 7 were taking placebo and 9 amoxicil-
lin. The overall compliance was no different in the
drug vs. placebo group (56/76 vs. 50/73)
(P 0.59).
The demographic data of the study groups are
shown in Table 1. There was no difference in mean
age or gravidity (P 0.33) in the groups. The
racial distribution was similar for the groups
(/ 0.S7).
The pregnancy outcomes are summarized in Ta-
bles 2 and 3. One patient in the placebo group had
an unexplained antepartum demise of both twins at
35 weeks. There were 2 neonatal deaths in the
amoxicillin/clavulanic acid group. The first death
occurred in a twin gestation delivered at 30 weeks
(1,695-g male). This infant died on day-of-life 12
from sepsis, being diagnosed as having congenital
leukemia. The sibling was a 1,535-g female who
did well. The other neonatal death was a small-for-
gestational-age, 1,960-g male delivered at 36 weeks
who died on day-of-life 4. The cause of death was
necrotizing enterocolitis due to a midgut volvulus
that resulted in a complete bowel obstruction. This
infant’s cotwin, also small for gestational age, was a
1,920 g-male who was noted to have chordee. Nine
neonates with normal cotwins had structural abnor-
malities. Table 2 illustrates the outcome data in-
cluding the numbers of patients delivering at vari-
ous gestational ages. The mean gestational ages at
delivery in the drug and placebo groups were sim-
ilar (35.9 weeks and 35.7 weeks, respectively). No
significant difference in the rate of delivery <30
weeks was found in the 2 groups (5/76 vs. 4/73,
P 0.75); the 95% confidence intervals for the
groups were 2.3-15.7% and 1.6-14% for the drug
and placebo groups, respectively. We also found no
significant difference in the rate of delivery <34
weeks in the 2 groups (14/76 vs. 19/73, P 0.34);
the 95% confidence intervals were 11.2-30.9%
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TABLE 2. Maternal outcome
Amoxicillin/clavulanic acid
Total 24-week entry
Outcome (N 71) (N 39)
28-week entry
(N 3)
Placebo
Total 24-week entry 28-week entry
(N 72) (N 36) (N 36)
Mean gestational age at delivery 35.9 35.6
(weeks)
25-28 weeks (%) 0 (0) 0 (0)
29-30 weeks (%) 5 (7) 3 (8)
31-33 weeks (%) 7 (I 0) 3 (8)
34-36 weeks (%) 24 (34) 16 (41)
37-39 weeks (%) 31 (44) 17 (44)
>40 weeks (%) 4 (6) 0 (0)
Prematrue rupture of membranes 7 (10) 5 (I 3)
(%)
Chorioamnionitis (%) (I) 0 (0)
Cesarean delivery (%) 46 (65) 23 (59)
36.2 35.7 35.4 35.7
0 (0) 2 (3) 2 (6) 0 (0)
2 (6) 2 (3) (3) (3)
4 (12) 8 (i m) 3 (8) 5
8 (24) 33 (46) 17 (47) 16 (44)
14 (44) 25 (3S) 13 (36) 12 (33)
4 (12) 2 (3) 0 (0) 2 (6)
2 (6) 4 (6) 2 (6) 2 (6)
(3) 4 (6) 2 (6) 2 (6)
23 (72) 43 (60) 26 (72) 17 (47)
TABLE 3. Neonatal outcome
Amoxicillin/clavulanic acid
Total
Outcome (N 142)
24-week entry 28-week entry
(N 78) (N 64)
Placebo
Total
(N 140)
24-week entry 28-week entry
(N 70) (N 70)
Mean birth weight (g) 2,358 2,323 2,401 2,344 2,362 2,325
750-,000 (%) 0 (0) 0 (0) 0 (0) 3 () 3 (4) 0 (0)
1,001-1,500 (%) 7 (5) 5 (6) 2 (3) 6 (4) 3 (4) 3 (4)
1,501-2,000 (%) 24 (17) 13 (17) II (17) 26 (19) 10 (14) 16 (23)
2,001-2,500 (%) 53 (37) 30 (39) 23 (36) 49 (35) 22 (31) 27 (39)
>2,501 (%) 58 (41) 30 (39) 28 (44) 56 (40) 32 (46) 24 (34)
Still births (%) 0 (0) 0 (0) 0 (0) 2 (I) 0 (0) 2 (3)
Neonatal deaths (%) 2 (I) (I) (2) 0 (0) 0 (0) 0 (0)
Mean hospital stay (days) 9.8 10.8 8.7 11.5 12.4 10.5
Hospital stay >7 days (%) 54 (38) 37 (47) 17 (27) 56 (40) 29 (41) 27 (39)
Respiratory distress syndrome (%) 8 (6) 3 (4) 5 (8) 6 (4) 2 (3) 4 (6)
Sepsis (%) 5 (4) 3 (4) 2 (3) 4 (3) 2 (3) 2 (3)
aSee text for details.
bRequiring intubation and diagnosed by neonatologist.
and 17.2-39.1% for the drug and placebo groups,
respectively. The rate of premature rupture of the
membranes (PROM) before labor and chorioam-
nionitis was not significantly different in the drug
and placebo groups (P--- 0.38 and 0.37, respec-
tively).
The neonatal outcomes are summarized in Table
3. There was no difference in mean weight in the
drug vs. placebo group (2,358 vs. 2,344 g,
P 0.86); the 95% confidence intervals were
2,278-2,438 and 2,252-2,435 g, respectively. In
addition, there was no difference in length of nurs-
ery stay using a cutoff of 6 days (P 0.76). The
overall incidence of respiratory distress syndrome
was no different (8/142 vs. 5/140, P 0.57). The
incidence of neonates with sepsis was also similar in
the drug vs. placebo group (5/142 vs. 4/140,
P 1.07). The perinatal mortality rate was 14.2
(4/282).
DISCUSSION
Preterm labor is the leading cause of perinatal mor-
bidity and mortality. In twin gestations, the peri-
natal mortality is 4-fold that of singleton gestations
mainly because of an increased incidence of pre-
term labor. 1,). Various attempts have been made to
decrease this incidence including prophylactic bed
rest, cervical cerclage, various tocolytic agents, and
home uterine activity monitoring.
9-16 None has
shown any clear beneficial effects although the rate
of preterm delivery has been found to be decreased
with home uterine activity monitoring.9’ Some
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investigators have suggested that this effect may be
due to frequent contact with health-care providers,
not to the monitoring device.
17 Recently, a reduc-
tion in very low birth weight deliveries and perina-
tal mortality in a specialized, multidisciplinary twin
clinic was reported.
18
The cause of preterm labor is unknown. Recent
studies suggest a link between subclinical infection
and prematurity.
2 There have been a variety of
cervicovaginal, upper-genital-tract, and amniotic-
fluid microorganisms associated with preterm de-
livery.
3
Antibiotic intervention trials have been con-
ducted in antepartum singleton pregnancies with
high-risk factors for preterm delivery.
19-23 A study
of patients with positive cervical cultures for Myco-
plasma treated with erythromycin revealed a signif-
icantly lower rate of PROM.
19 In 2 studies of
patients with positive chlamydial cultures who were
treated, the rates of preterm labor, small-for-ges-
tional-age infants, and PROM were lower. 21’22
Other studies using antibiotics as an adjunct to
tocolysis in patients in preterm labor have shown a
delay in delivery, but no statistically significant
decrease in perinatal mortality or increase in birth
weight. 4’2-2s Whether or not an increase in the
length of gestation has any long-term benefit for
the infant is unknown. In patients with positive
vaginal-swab cultures for M. homin# or Ure-
aplasma urealyticum, treatment with erythromycin
resulted in a statistically significant greater birth
weight,z
It has been hypothesized that mechanical forces
in twin pregnancy may cause premature cervical
dilation leading to an increased likelihood of as-
cending infections. Romero and coworkers
6 found
that 1.9% ofamniotic-fluid cultures in twin gesta-
tions with preterm labor were positive. These pa-
tients had a high incidence of respiratory distress
syndrome and lower mean birth weight.
The pregnancy outcomes of the present study
compare favorably with those of recently published
studies of twin pregnancies, l’18 Since neither
tocolysis nor home uterine monitoring was em-
ployed in our study, the frequent patient contact by
health-care providers, as suggested by others, may
indeed have had a beneficial effect. 9’ 10,18
The present study demonstrated no effect of the
antibiotic regimen on prolongation of pregnancy or
neonatal outcome. It is possible that a different or
longer antibiotic regimen may have shown a differ-
ence. In addition, our observations in an economi-
cally disadvantaged population might differ from
those in a more stable, middle-class population.
Since the assumption that all preterm labor is
caused by infection is probably not true in all cases,
as demonstrated by Romera et al.,6 using this as-
sumption in the power calculation may not rule out
a [3 error. Since no microorganism tests were ob-
tained for this study, more specific tests for bacte-
rial infections might result in identifying patients at
higher risk for preterm labor caused by infection.
The potential problems with compliance were
considered in determining the treatment regimen.
In the 6-week erythromycin protocol from Brigham
and Women’s Hospital, fewer than half of their
patients were compliant.
17 The changes in normal
bacterial flora resulting in fungal overgrowth and
bacterial resistance make long antibiotic therapy
impractical and potentially harmful. Amoxicillin/
clavulanic acid was chosen for its broad-spectrum
coverage, its safety in pregnancy, and its better
toleration compared with erythromycin.
Based on the results of this study, the routine
prophylactic use of amoxicillin/clavulanic acid to
prevent preterm delivery in twins cannot be recom-
mended.
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